Recent advances in developing polymeric micelles for treating cancer: breakthroughs and bottlenecks in their clinical translation.

Elsevier BV
Publication Type:
Journal Article
Drug Discov Today, 2022
Issue Date:
Filename Description Size
1-s2.0-S1359644622000459-main.pdfPublished version1.94 MB
Adobe PDF
Full metadata record
Polymeric micelles (PMs) have been explored pre-clinically for the delivery of chemotherapeutics to treat cancer. Their unique features, such as easy surface functionalization, stimuli-responsiveness, good stability, ability to modify drug release, enhanced permeation and retention effect, and potential to encapsulate more than one type of therapeutic molecules at a time, make them unique carriers for the targeted delivery or for enhancing the bioavailability of chemotherapeutics. PMs can also be used as theranostic nanocarriers for the mapping of drug therapy along with tumor imaging in patients with cancer. This review focuses on the limitations of existing treatment strategies and on innovative approaches employed for the functionalization of PMs for targeting cancer cells. In addition, the bottlenecks associated with the translation of PMs from the laboratory to clinics are also discussed.
Please use this identifier to cite or link to this item: